Who Might Benefit: Clinical Scenarios and Provider Decision-Making Combination therapy is sometimes considered for patients with severe obesity who have shown inadequate weight loss response to monotherapy alone, significant metabolic dysfunction, or type 2 diabetes requiring dual mechanisms
There are many drugs in the GLP-1 class, however, most are only available as injectable medications
It has a network of primary care doctors and nurse practitioners in more than 40 health specialties, along with labs and imaging centers, and includes both virtual and in-person care
Wegovy once-daily pill formulation was approved in December 2025
The Novo Nordisk Wegovy Savings Card program is a reliable source for potential savings on Wegovy prescriptions, offering discounts or even free access for those who qualify
The regulatory backdrop is the story right now